92 related articles for article (PubMed ID: 15116286)
1. Initial therapy for human immunodeficiency virus: broadening the options.
Sension M
HIV Clin Trials; 2004; 5(2):99-111. PubMed ID: 15116286
[TBL] [Abstract][Full Text] [Related]
2. An update and review of antiretroviral therapy.
Piacenti FJ
Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488
[TBL] [Abstract][Full Text] [Related]
3. Reviving protease inhibitors: new data and more options.
Murphy RL
J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S43-52; quiz S53, S55-6. PubMed ID: 12946064
[No Abstract] [Full Text] [Related]
4. Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Khanlou H; Bhatti L; Farthing C
J Acquir Immune Defic Syndr; 2006 Jan; 41(1):124-5. PubMed ID: 16340485
[No Abstract] [Full Text] [Related]
5. Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection.
Med Lett Drugs Ther; 2003 Nov; 45(1169):90-2. PubMed ID: 14603099
[No Abstract] [Full Text] [Related]
6. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
[TBL] [Abstract][Full Text] [Related]
7. Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs.
Belperio PS; Mole LX; Boothroyd DB; Backus LI
J Manag Care Pharm; 2009 May; 15(4):323-34. PubMed ID: 19422272
[TBL] [Abstract][Full Text] [Related]
8. New antiretroviral agents.
Gallant JE
Hopkins HIV Rep; 2001 Mar; 13(2):2, 16. PubMed ID: 12184261
[No Abstract] [Full Text] [Related]
9. The continuing evolution of HIV therapy.
Boyle BA
AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692
[No Abstract] [Full Text] [Related]
10. Trends in uptake of recently approved antiretrovirals within a national healthcare system.
Belperio PS; Mole LA; Boothroyd DB; Backus LI
HIV Med; 2010 Mar; 11(3):209-15. PubMed ID: 19863620
[TBL] [Abstract][Full Text] [Related]
11. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
12. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.
Pierone G; Urban T; Martin A; Mieras J; Kantor C
HIV Clin Trials; 2008; 9(2):140-1. PubMed ID: 18474499
[No Abstract] [Full Text] [Related]
13. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
15. Some existing drugs work on resistant HIV.
AIDS Alert; 2000 Jan; 15(1):10-2. PubMed ID: 11366357
[TBL] [Abstract][Full Text] [Related]
16. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.
Saag MS
Clin Infect Dis; 2006 Jan; 42(1):126-31. PubMed ID: 16323102
[TBL] [Abstract][Full Text] [Related]
17. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.
Clotet B
AIDS Rev; 2004; 6(3):123-30. PubMed ID: 15595429
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.
Calza L; Vanino E; Salvadori C; Manfredi R; Colangeli V; Cascavilla A; Di Bari MA; Motta R; Viale P
HIV Clin Trials; 2014; 15(1):1-13. PubMed ID: 24518210
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.
Shuter J; Sarlo JA; Rode RA; Zingman BS
HIV Clin Trials; 2009; 10(3):135-42. PubMed ID: 19632952
[TBL] [Abstract][Full Text] [Related]
20. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
